India Pharmaceuticals Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Patent Cliff of Legacy Blockbusters Fuels Generic Penetration

The India pharmaceuticals market is poised to benefit as established medicines lose patent protection, creating opportunities for domestic companies to launch generic alternatives. Semaglutide is expected to lose patent protection in India in March 2026, prompting several domestic companies to introduce generic versions shortly thereafter. Zydus Lifesciences plans to launch an adjustable, reusable multi-dose pen priced at INR 2,200 per month (USD 26), according to the company. The supplied material identifies Zydus Lifesciences, Sun Pharma, Dr. Reddy’s, and Mankind Pharma as early participants in this opportunity. Companies that secure timely regulatory approvals and build reliable retail distribution networks are likely to gain an early market position before price competition intensifies. This development is expected to support the India pharmaceuticals market by expanding patient access to generic semaglutide and driving volume growth for local manufacturers.

Government PLI Schemes Accelerating Domestic API & Formulation Capacity

The Production Linked Incentive (PLI) program continues to strengthen domestic manufacturing capacity for critical pharmaceutical ingredients and formulations. According to government information, 39 bulk-drug projects covering 28 critical APIs are expected to be commissioned by June 2026. These projects are designed to build capacity for Penicillin-G, Clavulanic Acid, Rifampicin, Atorvastatin, and other essential intermediates. Aurobindo Pharma’s Penicillin-G facility in the Kakinada SEZ has a planned capacity of 15,000 MT per year, supported by an investment of INR 2,270.1 crore (USD 270 million). This capacity expansion could support the India pharmaceuticals market by improving supply reliability, ensuring quality compliance, and strengthening export-oriented production. However, the commercial viability of these investments will depend on the ability of new facilities to secure sustained demand beyond the replacement of individual imports.

Rapid Chronic–Disease Incidence (Diabetes, CVD) Expands Long-Term Demand

Chronic conditions generate sustained demand for medicines used to manage diabetes, cardiovascular diseases, and related complications. Government data indicate that non-communicable diseases account for 56.7% of deaths in India, while cardiovascular diseases account for nearly 31%. The rising prevalence of diabetes further increases the need for therapies that address multiple related conditions. Patients with diabetes and hypertension typically require long-term treatment and recurring prescription refills, creating a consistent demand base. Online platforms and retail pharmacies support access to these therapies by facilitating timely prescription renewals. This sustained need for chronic disease management provides the India pharmaceuticals market with a durable demand base across branded generics and chronic-care products.

Pay-For-Performance Tendering by Large Hospital Chains

Digital pharmacy services are improving refill convenience for patients requiring recurring treatment. Tata 1mg, PharmEasy, and Apollo 24|7 are among the operators identified in the supplied material that are developing integrated digital health and medicine delivery ecosystems. Their platforms offer prescription uploads, refill reminders, and home delivery, reducing the effort required to access chronic medications. These services are particularly relevant in urban areas, where digital health adoption and delivery infrastructure are more advanced. In addition to prescription medications, these platforms support over-the-counter (OTC) wellness and self-care purchases. As a result, online channels may expand faster than traditional dispensing channels in the India pharmaceuticals market, while retail pharmacies remain critical for immediate fulfillment.

Frequent Retail Price Caps under NLEM Revisions Squeeze Margins

Price regulations continue to constrain margins on scheduled medicines, particularly in high-volume therapy areas. Effective April 1, 2025, the NPPA revised ceiling prices for 906 scheduled formulations and 14 intravenous formulations^[1]. Government information also highlighted a 1.7% WPI-linked adjustment and patient savings associated with the earlier NLEM 2022 revision. In addition, ceiling-price decisions may affect medicines added or revised outside the annual adjustment cycle. As a result, manufacturers with significant exposure to scheduled products may need to expand their portfolios of non-scheduled and differentiated formulations to safeguard profitability. Although these measures improve patient affordability, they continue to limit revenue realization in the India pharmaceuticals market.

Compliance Gaps with Revised Schedule M cGMP Audits

Revised Schedule M requirements elevate the quality standards that pharmaceutical manufacturing plants must meet. The Ministry of Health and Family Welfare notified the revised requirements in December 2023, establishing separate implementation timelines for large manufacturers and eligible MSMEs^[2]. Compliance is particularly critical for facilities that support high-volume generic drug demand. Manufacturers requiring plant upgrades may incur additional capital expenditure and face operational challenges during the transition. Risk-based inspections further emphasize the need for robust documented quality systems and timely corrective actions to sustain operations. The Indian pharmaceuticals market could face localized supply constraints if non-compliant facilities are temporarily unable to manufacture essential products.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

India Pharmaceuticals Market Segment Analysis

Anti-infectives are projected to account for 34.11% of the India pharmaceuticals market in 2025, supported by sustained demand for commonly dispensed medicines. The continued burden of infectious diseases and the high volume of prescriptions filled through community pharmacies underpin the segment’s leading position. Cardiovascular and anti-diabetic medicines also represent key therapy areas, as chronic conditions require ongoing treatment. Gastrointestinal and pain medicines generate frequent purchases across retail and online channels. Respiratory treatments are gaining relevance as inhalation products receive increased attention, further expanding the prescription base of the India pharmaceuticals market.

Oncology is forecast to grow at a CAGR of 8.22% through 2031, making it the fastest-growing therapeutic area in the analysis. Greater biosimilar availability, specialty treatments, and the increasing adoption of precision medicine are expected to support this growth. Dr. Reddy’s is expected to launch NIVORZ, a nivolumab biosimilar approved by the DCGI for 12 cancer indications, in September 2026 [3]. Cipla is also expected to enter into a license and supply agreement for TQB2102, a HER2 bispecific antibody-drug conjugate, in August 2026. These developments underscore the growing strategic importance of biologics and antibody-drug conjugates in domestic oncology competition and may place manufacturers without biologics capabilities at a competitive disadvantage.

Prescription drugs accounted for 61.26% of drug-type revenue in 2025, supported by a broad base of generic medicines and a smaller portfolio of patented and specialty therapies. Multinational companies drive demand for selected branded therapies through targeted engagement with medical professionals and hospitals, while domestic companies leverage established prescription brands to maintain recognition among physicians and pharmacies. Chronic care treatments further support prescription dispensing, as regulated medicines remain integral to patient treatment in the India pharmaceuticals market.

OTC drugs are forecast to grow at a CAGR of 7.24% through 2031, driven by expanding opportunities across organized retail pharmacies and digital platforms. Retail pharmacies can cross-sell wellness and self-care products to existing customers, while digital platforms can offer bundles combining supplements and repeat-purchase products. The supplied material linked this trend to higher average order values across selected wellness categories. Semaglutide’s patent expiry is also expected to create a self-pay opportunity, increasing the convergence of consumer-led purchases and traditional pharmacy sales.

Tablets accounted for 36.25% of formulation revenue in 2025, supported by their cost efficiency, product stability, and widespread familiarity among patients and pharmacies. They remain the preferred formulation for anti-infective, cardiovascular, anti-diabetic, and pain management therapies. Capsules cater to select premium and nutraceutical product segments, while syrups and suspensions continue to play an important role in pediatric dosing. Other formulations include newer delivery formats designed to address specific patient needs; however, tablets retain a leading position in the Indian pharmaceutical market.

Injectables are projected to grow at a CAGR of 6.98% through 2031, driven by increasing demand for oncology biologics, biosimilar infusions, and hospital-administered treatments. Dr. Reddy’s Aurigene entered into a long-term manufacturing and supply agreement with a global pharmaceutical company for annual volumes of 18 million units, primarily focused on injectable products. Such agreements enable manufacturers to strengthen complex production capabilities while sharing commercial risk. Rising hospital utilization and biosimilar approvals are expected to expand injectable capacity and shift the formulation mix toward high-value therapies.

Oral products are projected to account for 74.33% of revenue in 2025, supported by the widespread use of tablets and capsules for treating common acute and chronic conditions. Familiarity among patients and alignment with established retail pharmacy dispensing practices further support their adoption. Anti-infective, anti-diabetic, and cardiovascular therapies contribute significantly to oral product volumes. Although parenteral products remain essential for inpatient care and complex specialty therapies, oral medicines continue to form the volume base of the India pharmaceuticals market.

Inhalational products are forecast to grow at a CAGR of 9.13% through 2031, driven by the increasing focus on asthma and chronic obstructive pulmonary disease (COPD) treatment. Cipla’s Rotahaler platform strengthens its established position in the domestic inhalation therapy segment. Zydus is expected to launch REVAHALE, a once-daily nebulized long-acting muscarinic antagonist (LAMA) treatment for COPD, in August 2026. Device-differentiated products can address the needs of patients who cannot use standard inhalers effectively, while clinical guidance can support the broader adoption of inhaled therapies.

Retail pharmacies are projected to account for 64.57% of distribution channel revenue in 2025, supported by their proximity to clinics, hospitals, and residential neighborhoods. This accessibility enables patients to fill prescriptions and purchase OTC products during the same visit. Hospital pharmacies continue to play a critical role in inpatient care, oncology, and other specialty therapies. Retail outlets also remain a key patient access channel, particularly for consumers seeking pharmacist guidance, reinforcing their position as a primary distribution route across the India pharmaceutical market.

Online pharmacies are forecast to expand at a CAGR of 9.45% through 2031, driven by digital prescription processing and doorstep delivery services that improve medicine access for repeat users. Tata 1mg, PharmEasy, and Apollo 24|7 have established integrated platforms offering consultations, prescription management, and medicine fulfillment. In addition, quick-commerce services can facilitate convenient purchases of OTC and wellness products. Subject to regulatory clarity and secure prescription processes, these platforms can distinguish convenience-driven consumer purchases from standard prescription fulfillment.

Geographic Analysis

West India accounted for 32.24% of the India pharmaceuticals market share in 2025, supported by its established manufacturing and export ecosystem. Gujarat maintains a strong API and chemical synthesis base across locations such as Ankleshwar and Vadodara, while Maharashtra’s Mumbai-Pune corridor integrates research activities, corporate headquarters, and manufacturing capabilities. Government investment support has further strengthened pharmaceutical projects across these western states. Well-developed export logistics also connect regional manufacturing facilities with markets in Africa, Latin America, and ASEAN countries, supporting both domestic pharmaceutical supply and overseas shipments.

South India is projected to grow at a CAGR of 7.27% through 2031, driven by expanding manufacturing capacity and rising treatment demand. Telangana supports pharmaceutical research and manufacturing through the Hyderabad ecosystem, while Andhra Pradesh is expanding bulk drug production capacity and Karnataka continues to attract biosimilar investments. Higher chronic care needs in certain southern states, as identified in the supplied material, may further support medicine consumption. The region’s technical workforce and established life sciences ecosystem also enable companies to develop complex products, reinforcing its growth outlook.

North India held an estimated 26% revenue share in 2025, according to the supplied draft, supported by pharmaceutical expenditure, institutional procurement, and over-the-counter (OTC) wellness demand in Delhi-NCR. Uttarakhand and Himachal Pradesh also maintain a sizeable MSME formulation manufacturing base, although Schedule M compliance readiness remains important for these clusters. East and Northeast India represented the smallest regional contribution in the supplied material. However, Odisha and West Bengal are expanding pharmaceutical MSME capacity and strengthening logistics connectivity. Across all regions, national regulatory oversight continues to govern product approvals and compliance.